Denali Therapeutics Announces Data Presentations On Enzyme Transportvehicle™ Programs For Hunter Syndrome, Sanfilippo Syndrome Type A And Pompe Disease At Upcoming 2026 Worldsymposium™
Denali Therapeutics Inc DNLI.O:
DENALI THERAPEUTICS ANNOUNCES DATA PRESENTATIONS ON ENZYME TRANSPORTVEHICLE™ PROGRAMS FOR HUNTER SYNDROME, SANFILIPPO SYNDROME TYPE A AND POMPE DISEASE AT UPCOMING 2026 WORLDSYMPOSIUM™
DENALI THERAPEUTICS INC: FDA DECISION ON TIVIDENOFUSP ALFA BLA EXPECTED BY APRIL 5, 2026
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.